Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29713943 | 0.88 | SIGMAR1 (0.56) | SIGMAR1LMNAALDH1A1POLBGAA | |
| SCHEMBL8944547 | 0.88 | SIGMAR1 (0.56) | SIGMAR1LMNAALDH1A1POLBGAA | |
| SCHEMBL11990398 | 0.87 | SIGMAR1 (0.47) | SIGMAR1ALDH1A1POLB | |
| SCHEMBL27007117 | 0.86 | SIGMAR1 (0.48) | SIGMAR1LMNAALDH1A1 | |
| SCHEMBL25154604 | 0.85 | SIGMAR1 (0.57) | SIGMAR1LMNAALDH1A1POLBGAA | |
| SCHEMBL21315836 | 0.85 | SIGMAR1 (0.57) | SIGMAR1LMNAALDH1A1POLBGAA | |
| SCHEMBL4283405 | 0.85 | SIGMAR1 (0.57) | SIGMAR1LMNAALDH1A1POLBGAA | |
| SCHEMBL1665118 | 0.84 | HDAC8 (0.56) | SIGMAR1 | |
| SCHEMBL1873619 | 0.84 | HDAC8 (0.56) | SIGMAR1 | |
| SCHEMBL4848163 | 0.83 | OPRD1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113840820-B | Phthalazinone compounds and uses thereof | ST制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| US-11591476-B2 | In-vivo probe for real time longitudinal monitoring of inducible nitric-oxide synthase in living cells and animals | PANDA KOUSTUBH (IN) | 2023-02-28 | — | — | US | disclosed |
| US-20220235011-A1 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2022-07-28 | — | — | US | disclosed |
| EP-3978480-A1 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | ST Pharm Co., Ltd. (KR) | 2022-04-06 | — | — | EP | disclosed |
| CN-113840820-A | Phthalazinone compounds and uses thereof | ST制药株式会社 | 2021-12-24 | — | — | CN | disclosed |
| WO-2020242245-A1 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | 에스티팜 주식회사 | 2020-12-03 | — | — | WO | disclosed |
| US-20190309169-A1 | NOVEL IN-VIVO PROBE FOR REAL TIME LONGITUDINAL MONITORING OF INDUCIBLE NITRIC-OXIDE SYNTHASE IN LIVING CELLS AND ANIMALS | PANDA KOUSTUBH (IN) | 2019-10-10 | — | — | US | disclosed |
| WO-2018092034-A1 | NOVEL IN-VIVO PROBE FOR REAL TIME LONGITUDINAL MONITORING OF INDUCIBLE NITRIC-OXIDE SYNTHASE IN LIVING CELLS AND ANIMALS | PANDA KOUSTUBH (IN) | 2018-05-24 | — | — | WO | disclosed |
| CN-103214473-A | Dibenzo[b,f][1,4]oxazapine compounds | ARYX THERAPEUTICS INC | 2013-07-24 | — | — | CN | disclosed |
| CN-101641350-B | Dibenzo [ b, f ] [1,4] oxazepine compounds | ARYX THERAPEUTICS INC | 2012-11-28 | — | — | CN | disclosed |
| US-20030069210-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-10 | — | — | US | disclosed |
| US-20030060452-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-03-27 | — | — | US | disclosed |
| US-6525042-B1 | Inhibits an activated coagulation factor FXa; anticoagulant, antithrombotic | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| US-20030027794-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-02-06 | — | — | US | disclosed |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-12-05 | — | — | US | disclosed |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-11-07 | — | — | US | disclosed |
| US-6432947-B1 | NERVOUS SYSTEM DISORDERS; MUSCLE RELAXANTS; ANTIDIABETIC AGENTS | BERLEX LABORATORIES, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| EP-1031563-A1 | SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060452-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | SIGMAR1 784/4885LMNA 1821/4885ALDH1A1 328/4885 |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | SIGMAR1 784/4885LMNA 1821/4885ALDH1A1 328/4885 |
| US-20220235011-A1 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | SIRT6, SIRT1, SIRT2 | SIGMAR1 4423/4885LMNA 2949/4885ALDH1A1 1433/4885 |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | SIGMAR1 784/4885LMNA 1821/4885ALDH1A1 328/4885 |
| US-20030069210-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | SIGMAR1 784/4885LMNA 1821/4885ALDH1A1 328/4885 |
| US-20030027794-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | SIGMAR1 784/4885LMNA 1821/4885ALDH1A1 328/4885 |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | SIGMAR1 784/4885LMNA 1821/4885ALDH1A1 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.